Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14692533 | 0.85 | PSEN1 (0.30) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3199864 | 0.81 | ADRB2 (0.31) | CES2CES1 | |
| SCHEMBL28410212 | 0.81 | CES2 (0.42) | CES2CES1 | |
| SCHEMBL7170117 | 0.77 | ADRA2C (0.46) | — | |
| SCHEMBL22206827 | 0.75 | THRB (0.33) | — | |
| SCHEMBL31074205 | 0.72 | CES2 (0.46) | CES2CES1 | |
| SCHEMBL20646071 | 0.72 | CYP2C19 (0.31) | — | |
| SCHEMBL20879202 | 0.69 | CYP11B1 (0.31) | — | |
| SCHEMBL22766426 | 0.69 | ALDH1A1 (0.46) | — | |
| SCHEMBL31074206 | 0.69 | CES2 (0.44) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-7498320-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1781101-A2 | NOVEL NUCLEOSIDE DERIVATIVES | Metabasis Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-01-25 | — | — | US | disclosed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006033709-A2 | NOVEL NUCLEOSIDE DERIVATIVES | METABASIS THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1556393-A2 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-09-30 | — | — | US | disclosed |
| WO-2004041834-A2 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | CES2 738/4885CES1 196/4885PSEN1 2500/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | CES2 522/4885CES1 103/4885PSEN1 3922/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | CES2 228/4885CES1 87/4885PSEN1 3762/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | CES2 299/4885CES1 191/4885PSEN1 4395/4885 |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, CYP2F1 | CES2 325/4885CES1 226/4885PSEN1 3220/4885 |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, TYMP | CES2 334/4885CES1 237/4885PSEN1 3117/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | CES2 262/4885CES1 104/4885PSEN1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.